ULTRAVIST 370

Indications

• Diagnostic imaging of the vascular system
• Contrast-enhanced computed tomography (CT) scans
• Angiography
• Excretory urography

Dosage

Children: Refer to the BNF for Children for appropriate dosing information in paediatric patients.

Adults: The dosing of iopromide depends on the specific imaging procedure and patient characteristics. Refer to the BNF for detailed dosing guidelines.

Mechanism of action

Iopromide works by increasing the contrast of radiographic images through its iodine content, which absorbs X-rays. After intravascular injection, it enhances the visibility of blood vessels and tissues, allowing for clearer imaging during diagnostic procedures.

Pharmacodynamics

Following intravenous injection, opacification of the renal parenchyma begins within 1 minute. The excretion of iopromide is noticeable within 1 to 3 minutes, with optimal contrast observed in the calyces and collecting system occurring between 5 and 15 minutes. In patients with nephropathic conditions, the excretion rate may be unpredictable, with possible delays in opacification for several hours. The effectiveness of the contrast enhancement is directly related to the iodine concentration present in the targeted tissue.

Pharmacokinetics

Iopromide is primarily eliminated through renal excretion. The pharmacokinetics can vary significantly in patients with impaired renal function, which may affect the time taken for the contrast agent to be excreted and the subsequent imaging outcomes. Its distribution and elimination largely depend on the patient's renal capacity.

Contra-indications

• Hypersensitivity to iopromide or any of its components
• Severe renal impairment
• Uncontrolled hyperthyroidism or thyroid storm

Adverse effects

• Nausea
• Vomiting
• Headache
• Dizziness
• Injection site reactions
• Hypotension
• Allergic reactions
• Nephrotoxicity
• Thyroid dysfunction

Interactions

• May enhance the effects of anticoagulants
• Potential interaction with other nephrotoxic agents

Precautions

• Caution in patients with renal impairment
• Caution in patients with a history of allergic reactions to contrast media
• Adequate hydration should be ensured before and after administration
• Monitor renal function post-procedure

Pregnancy

Iopromide should only be used if the potential benefit justifies the potential risk to the fetus. It is recommended to avoid use in pregnancy unless necessary.

Breast-feeding

Iopromide is excreted in breast milk in small amounts. Caution should be exercised when administering to a nursing mother.

Storage

Store at room temperature (15-25 degrees Celsius). Protect from light. Do not freeze.

Formulations

• Iopromide 300 mg I/mL
• Iopromide 370 mg I/mL

Mechanism of action

Iopromide is a nonionic iodinated, water-soluble, radiographic contrast medium that is available in two stable, ready-to-use solutions of different concentrations (i.e., 300 mg I/mL and 370 mg I/mL). Following intravascular injection, iopromide provides radiographic opacification of the vasculature and extracellular space in the path of flow of the agent, allowing diagnostic assessment of the limbs and internal organs until significant dilution occurs.

Pharmacodynamics

After intravenous injection, opacification of the renal parenchyma begins within 1 minute. Excretion of the contrast agent becomes apparent in 1 to 3 minutes with optimal contrast in the calyces and collecting system occurring between 5 and 15 minutes. In nephropathic conditions, particularly when excretory capacity has been altered, the excretion rate varies unpredictably and opacification may be delayed for several hours after injection. the degree of contrast enhancement is related to the iodine concentration in the tissue of interest.